Macdonald James A, Fraser John F, Foot Carole L, Tran Khoa
Critical Care Research Group, The Prince Charles Hospital, Chermside QLD, Australia.
Chest. 2006 Aug;130(2):577-9. doi: 10.1378/chest.130.2.577.
Recombinant activated factor VII (rFVIIa) is a powerful hemostatic agent developed for use in hemophilia. It has been used increasingly in life-threatening hemorrhage in a variety of other settings in which conventional medical or surgical therapy is unsuccessful. This report describes the successful use of rFVIIa for pulmonary hemorrhage due to a focal bleeding source in a regional hospital where bronchial artery embolization or surgery were not available. rFVIIa may be a useful temporizing measure in the unstable patient with pulmonary hemorrhage without coagulopathic bleeding when conventional treatment is not immediately available.
重组活化因子VII（rFVIIa）是一种为血友病治疗而研发的强效止血剂。它越来越多地被用于常规内科或外科治疗无效的各种危及生命的出血情况。本报告描述了在一家无法进行支气管动脉栓塞或手术的地区医院，成功使用rFVIIa治疗因局灶性出血源导致的肺出血。当常规治疗无法立即实施时，rFVIIa对于患有肺出血且无凝血病性出血的不稳定患者可能是一种有用的临时措施。
